anxiety treatment
anxiety regulation
anxiety tests
Anxiety disorders
new targets
Importin-based Therapeutics Anxiety
development of new anxiolytic drugs
new avenues
new molecular pathway
approved drugs
new drug leads
importin mutant line
Importin-dependent transport mechanisms
initial identifications of anxiolytic drugs
related molecules
anxiolytic activities
roles of importins
comprehensive phenotyping of importin mouse mutants
stress-related conditions
additional IP protection
neurotransmitter levels
commercialisation potential
interesting targets
therapeutic development
deregulation of size control pathways
synaptic mechanisms
variety of agents
behavioural control
pre-commercialisation tasks
neurotransmitter receptor systems
cell size sensing
HTS-compatible assay
nucleus
specific phenotype
significant health burden
follow-up analyses
synapse
consequences
axonal injury
availability
need
diversity of physiological contexts
effects
course
current ERC Advanced grant
long-term use
modern society
compounds
difficulty
suboptimal efficacy
pilot screen
functional analogs
aims
anxiolysis
date
discovery
final step
PoC